Please wait...
172
65
Offers Claimed: 165
Downloaded Today: 151
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Applies to glyburide: oral tablet
Along with its needed effects, glyburide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking glyburide:
Less common
Rare
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking glyburide:
Symptoms of overdose
Some side effects of glyburide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Incidence not known
For Healthcare Professionals
Applies to glyburide: compounding powder, oral tablet
GeneralLike all sulfonylureas, this drug may commonly cause hypoglycemia and in some case it may be severe. Proper patient selection, dose, and patient instructions are important to avoid hypoglycemic episodes.
MetabolicGlyburide:
Very rare (less than 0.01%): Disulfiram-like reaction
Frequency not reported: Hypoglycemia, hyponatremia, weight gain, lactic acidosis, syndrome of inappropriate antidiuretic hormone (SIADH) secretion
Sulfonylureas:
Frequency not reported: Hepatic porphyria
Neonatal Diabetes:
Very common (10% or more): Hypoglycemia
GastrointestinalAdverse gastrointestinal effects occur in about 1% to 2% of patients and appear to be dose related; they may subside following a dose reduction. Pancreatitis has been reported rarely.
Common (1% to 10%): Nausea, vomiting, epigastric fullness or sensation of pressure, abdominal pain, anorexia, dyspepsia, diarrhea, heartburn
Rare (less than 0.1%): Pancreatitis
Neonatal Diabetes:
Very common (10% or more): Transitory diarrhea, abdominal pain, vomiting, dyspepsia
Common (1% to 10%): Tooth discoloration
HypersensitivityVery rare (less than 0.01%): Allergic vasculitis
Frequency not reported: Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, angioedema, arthralgia, myalgia, vasculitis, erythema multiforme, erythema nodosum, bullous eruptions, exfoliative dermatitis, photosensitivity, Stevens-Johnson syndrome
Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5 % of patients during clinical trials. In some cases these were transient and disappeared despite continue therapy. Hypersensitivity reactions affecting the skin usually occur within the first 6 weeks of treatment with a sulfonylurea.
DermatologicGlyburide:
Common (1% to 10%): Allergic skin reactions including pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions
Frequency not reported: Alopecia/hypotrichoses, increased sweating, facial edema, angioedema, bullous reactions, erythema multiforme, exfoliative dermatitis
Sulfonylureas:
-Frequency not reported: Porphyria cutanea tarda, photosensitivity reactions
Allergic skin reactions including pruritus, erythema, urticaria, morbilliform, erythematous and maculopapular and bullous skin eruptions or psoriasiform drug eruptions occurred in 1.5 % of patients during clinical trials. These may be transient and may disappear despite continued therapy. Bullous reactions, erythema multiforme, and exfoliative dermatitis have been reported. If skin reactions persist, this drug should be discontinued.
OcularChanges in accommodation and/or blurred vision are thought to be related to fluctuations in glucose levels.
Frequency not reported: Changes in accommodation and/or blurred vision, diplopia, visual disturbances, blindness
HematologicGlyburide:
Postmarketing reports: Hemolytic anemia
Sulfonylureas:
Frequency not reported: Leukopenia, agranulocytosis, thrombocytopenia, thrombocytopenia purpura, eosinophilia, bone marrow aplasia, coagulation disorders, hemolytic anemia, aplastic anemia, anemia, pancytopenia
HepaticGlyburide:
Rare (less than 0.1%): Cholestatic jaundice, hepatitis
Frequency not reported: Liver function abnormalities including isolated transaminase elevations
Postmarketing reports:
Sulfonylureas:
Frequency not reported: Increased liver enzymes (AST, ALT), abnormal liver function, cholestasis, cholestatic hepatitis, granulomatous hepatitis, bilirubinemia
Neonatal Diabetes:
Very common (10% or more): Transient increased transaminases
RenalFrequency not reported: Abnormal renal function, acute renal failure
MusculoskeletalFrequency not reported: Arthralgia, arthritis
Nervous systemFrequency not reported: Paresthesia, tremor, convulsions, encephalopathy, confusion, headache, cerebrovascular disorders
OtherFrequency not reported: Deafness, fever
PsychiatricFrequency not reported: Acute psychosis
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.
Source: Drugs.com Glyburide (www.drugs.com/glyburide.html).
August 27, 2020
May 17, 2022
May 17, 2022
May 17, 2022
May 17, 2022
May 16, 2022